NEW YORK — The US Food and Drug Administration on Thursday granted separate Emergency Use Authorizations (EUAs) for PCR-based SARS-CoV-2 tests developed by South Korean diagnostic test makers BioCore, SolGent, and Seasun Biomaterials.
The BioCore 2019-nCoV Real Time PCR Kit is designed to detect the SARS-CoV-2 N and RdRp genes in upper and lower respiratory specimens including nasopharyngeal swabs, sputum, and bronchoalveolar lavage.